Most of what this roster sells is not the branded drug — that is most of why it costs what it costs. The question that follows is whether a copy does what the original does, and the usual answer is that nobody has checked. Here is what it looks like when somebody does.
The trial
Twenty-one centers in India enrolled 270 adults with a BMI of 30 or above, or 27 or above with hypertension, dyslipidemia or type 2 diabetes, and randomized them 2:1 to a synthetic semaglutide injection or to Wegovy, escalating from 0.25 mg to 2.4 mg weekly. [1] The primary endpoint was percentage weight change at 24 weeks. The trial was prospectively registered before it began.
Two hundred and forty-six of the 267 randomized patients completed. Weight fell 13.8% on the test product and 14.1% on the reference, a least-squares mean difference of 0.26 percentage points with a 95% CI of −0.86 to 1.39 — inside the prespecified non-inferiority margin. The proportion reaching at least 5% weight loss was 96.40% against 98.80%, and at least 10% was 80.60% against 80.00%. Treatment-emergent adverse events occurred in 72.30% and 76.70%, mostly gastrointestinal. Immunogenicity was among the stated objectives; the abstract does not report its result, so this page does not either.
Why it is worth reading anyway
Because it establishes a standard rather than a comfort. Until now the argument about non-originator semaglutide has been conducted almost entirely in the abstract — chemistry arguments, regulatory categories, and confident claims in both directions with no clinical comparison behind them. This is a clinical comparison. It shows that the question is answerable and what answering it costs: a registered protocol, a named reference product, a prespecified margin, and two hundred and seventy people.
That is the bar. Set against it, the US compounded market’s evidence base is easier to describe: there isn’t one. The regulatory categories that permit compounding are about who may prepare a drug and under what conditions, not about whether the result performs — the 503A and 503B distinction is frequently quoted as though it settled efficacy, and it does not address it.
What the trial does not cover
Twenty-four weeks is short for a weight-loss trial; the landmark studies ran 68 or 72. One country, one manufacturer, one product. And a non-inferiority result is a statement about a margin, not a demonstration that two things are identical — the interval here runs from −0.86 to 1.39, which is consistent with the test product being slightly better and slightly worse.
None of that undermines it. It means the finding is what it says it is: at 24 weeks, on weight, in this population, the copy was not meaningfully worse.
What to take to a checkout
One question, and it is not about chemistry. Ask what evidence exists for the specific product being sold — not for semaglutide, and not for compounding as a category. For almost everything in the price check the honest answer is none, which is a different thing from evidence of a problem and should not be confused with one.
The floor beneath that is lower still, and worth knowing about separately: sellers that ship with no prescription at all are a different market from the one this site tracks, and the distance between a registered head-to-head trial and that end of it is most of the pharmaceutical system.